Breast cancer is a global cause for concern owing to its high incidence around the world.
The alarming increase in breast cancer cases emphasizes the management of disease at …

Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United
States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

Background Population-based estimates of the risk of breast cancer associated with
germline pathogenic variants in cancer-predisposition genes are critically needed for risk …

PURPOSE Genetic testing for cancer risk has expanded rapidly. We examined clinical
genetic testing and results among population-based patients with breast and ovarian …

Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of
various types of malignant diseases. Mechanisms of PTX action represent several ways in …

Background The purpose of this study was to estimate precise age-specific tubo-ovarian
carcinoma (TOC) and breast cancer (BC) risks for carriers of pathogenic variants in RAD51C …

Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Homologous recombination (HR) is a highly accurate DNA repair mechanism. Several HR
genes are established cancer susceptibility genes with clinically actionable pathogenic …

PURPOSE To develop recommendations for germline mutation testing for patients with
breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to …